company / mission statement
   


Vitateq Biotechnology GmbH, founded in 2000, is a research-driven biotechnology spin-off from the Medical University of Innsbruck. Our research centers around the function of the vitamin E-binding protein AFAMIN and explores the very promising diagnostic and therapeutic applications of this biomarker in cancer, infertility, pregnancy complications, metabolic, cardiovascular and neurodegenerative diseases.